Synergistic STING and cyto-IL-15 therapy

The STING-activating cyclic dinucleotide agonist ADU-S100 (MIW815; ML RR-S2 CDA) (MedChemExpress, Cambridge Bioscience Limited, Cambridge, UK) was diluted in HBSS (Hank’s balanced salt solution, vehicle) and was used at 50 µg (in 50µl) doses. IL-15 and cytotopically modified (cyto-IL-15) were produced in our laboratory as previously described (24 (link)), diluted in PBS and were used at 10 µg doses. Cyto-IL-15 is a version of IL-15 conjugated with a bis-myristoylated peptide to allow anchoring of IL-15 to cell membranes, which is in addition to IL-15 receptors binding. Currently a patent has been filled (P71020GB: KCL ref. 501/3048) for the combination of cyto-IL-15 with STING agonists in cancer treatment.

Free full text: Click here

Papaevangelou E., Esteves A.M., Dasgupta P, & Galustian C. (2023). Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models. Frontiers in Immunology, 14, 1196829.

Publication 2023

ML RR-S2 CDA

Agonists Cancer Cell membranes Dinucleotide Hbss Il 15 Il 15 receptors Peptide S100 Salt

Corresponding Organization : Guy's Hospital

Top 5 similar protocols

Variable analysis

independent variables

ADU-S100 (MIW815; ML RR-S2 CDA)
IL-15
Cyto-IL-15

dependent variables

Not explicitly mentioned

control variables

HBSS (Hank's balanced salt solution)

controls

Positive control: Not specified
Negative control: Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!